Literature DB >> 15692831

Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients.

Yukiko Nakajima1, Yoshiro Saito, Kisho Shiseki, Hiromi Fukushima-Uesaka, Ryuichi Hasegawa, Shogo Ozawa, Kenji Sugai, Masaaki Katoh, Osamu Saitoh, Teiichi Ohnuma, Mitsuru Kawai, Taisuke Ohtsuki, Chieko Suzuki, Narihiro Minami, Hideo Kimura, Yu-ichi Goto, Naoyuki Kamatani, Nahoko Kaniwa, Jun-ichi Sawada.   

Abstract

OBJECTIVE: Microsomal epoxide hydrolase (mEH) is an enzyme that detoxifies reactive epoxides and catalyzes the biotransformation of carbamazepine-10,11-epoxide (CBZ-epoxide) to carbamazepine-10,11-diol (CBZ-diol). Utilizing single nucleotide polymorphisms (SNPs) of the EPHX1 gene encoding mEH, we identified the haplotypes of EPHX1 blocks and investigated the association between the block haplotypes and CBZ-epoxide metabolism.
METHODS: SNPs of EPHX1 were analyzed by means of polymerase chain reaction amplification and DNA sequencing using DNA extracted from the blood leukocytes of 96 Japanese epileptic patients, including 58 carbamazepine-administered patients. The plasma concentrations of CBZ and its four metabolites were determined using high-performance liquid chromatography.
RESULTS: From sequencing all 9 exons and their surrounding introns, 29 SNPs were found in EPHX1. The SNPs were separated into three blocks on the basis of linkage disequilibrium, and the block haplotype combinations (diplotypes) were assigned. Using plasma CBZ-diol/CBZ-epoxide ratios (diol/epoxide ratios) indicative of the mEH activity, the effects of the diplotypes in each EPHX1 block were analyzed on CBZ-epoxide metabolism. In block 2, the diol/epoxide ratios increased significantly depending on the number of haplotype *2 bearing Y113H (P=0.0241). In block 3, the ratios decreased depending on the number of haplotype *2 bearing H139R (P=0.0351). Also, an increasing effect of a *1 subtype, *1c, was observed on the ratio.
CONCLUSION: These results show that some EPHX1 haplotypes are associated with altered CBZ-epoxide metabolism. This is the first report on the haplotype structures of EPHX1 and their potential in vivo effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15692831     DOI: 10.1007/s00228-004-0878-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

Review 1.  The predictive power of haplotypes in clinical response.

Authors:  R Judson; J C Stephens; A Windemuth
Journal:  Pharmacogenomics       Date:  2000-02       Impact factor: 2.533

Review 2.  Inheritance and drug response.

Authors:  Richard Weinshilboum
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

3.  Five novel single nucleotide polymorphisms in the EPHX1 gene encoding microsomal epoxide hydrolase.

Authors:  Kisho Shiseki; Masaya Itoda; Yoshiro Saito; Yukiko Nakajima; Keiko Maekawa; Hideo Kimura; Yu-ichi Goto; Osamu Saitoh; Masaaki Katoh; Teiichi Ohnuma; Mitsuru Kawai; Kenji Sugai; Taisuke Ohtsuki; Chieko Suzuki; Narihiro Minami; Shogo Ozawa; Jun-ichi Sawada
Journal:  Drug Metab Pharmacokinet       Date:  2003       Impact factor: 3.614

Review 4.  Epoxide hydrolases: biochemistry and molecular biology.

Authors:  A J Fretland; C J Omiecinski
Journal:  Chem Biol Interact       Date:  2000-12-01       Impact factor: 5.192

5.  Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine.

Authors:  E Spina; C Martines; A Fazio; R Trio; F Pisani; T Tomson
Journal:  Ther Drug Monit       Date:  1991-03       Impact factor: 3.681

6.  Seventy genetic variations in human microsomal and soluble epoxide hydrolase genes (EPHX1 and EPHX2) in the Japanese population.

Authors:  S Saito; A Iida; A Sekine; C Eguchi; Y Miura; Y Nakamura
Journal:  J Hum Genet       Date:  2001       Impact factor: 3.172

7.  Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm.

Authors:  Y Kitamura; M Moriguchi; H Kaneko; H Morisaki; T Morisaki; K Toyama; N Kamatani
Journal:  Ann Hum Genet       Date:  2002-05       Impact factor: 1.670

8.  Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity.

Authors:  V J Green; M Pirmohamed; N R Kitteringham; A Gaedigk; D M Grant; M Boxer; B Burchell; B K Park
Journal:  Biochem Pharmacol       Date:  1995-10-26       Impact factor: 5.858

9.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor.

Authors:  Jubao Duan; Mark S Wainwright; Josep M Comeron; Naruya Saitou; Alan R Sanders; Joel Gelernter; Pablo V Gejman
Journal:  Hum Mol Genet       Date:  2003-02-01       Impact factor: 6.150

10.  A cluster of three single nucleotide polymorphisms in the 3'-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities.

Authors:  L Frittitta; T Ercolino; M Bozzali; A Argiolas; S Graci; M G Santagati; D Spampinato; R Di Paola; C Cisternino; V Tassi; R Vigneri; A Pizzuti; V Trischitta
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

View more
  15 in total

1.  PharmGKB summary: carbamazepine pathway.

Authors:  Caroline F Thorn; Susan G Leckband; John Kelsoe; J Steven Leeder; Daniel J Müller; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

Review 2.  The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

Review 4.  Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease.

Authors:  Radka Václavíková; David J Hughes; Pavel Souček
Journal:  Gene       Date:  2015-07-26       Impact factor: 3.688

Review 5.  Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.

Authors:  Junji Saruwatari; Takateru Ishitsu; Kazuko Nakagawa
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-20

6.  The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients.

Authors:  Chahra Chbili; Anis Hassine; Aicha Laouani; Sana Ben Amor; Manel Nouira; Sofiène Ben Ammou; Saad Saguem
Journal:  Arch Med Sci       Date:  2016-05-20       Impact factor: 3.318

7.  Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.

Authors:  Vincent L M Yip; Henry Pertinez; Xiaoli Meng; James L Maggs; Daniel F Carr; B Kevin Park; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2020-12-14       Impact factor: 4.335

8.  Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients.

Authors:  Antonietta Caruso; Chiara Bellia; Alessia Pivetti; Luisa Agnello; Federica Bazza; Concetta Scazzone; Giulia Bivona; Bruna Lo Sasso; Marcello Ciaccio
Journal:  Pharmgenomics Pers Med       Date:  2014-04-02

9.  Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.

Authors:  Armond Daci; Giangiacomo Beretta; Driton Vllasaliu; Aida Shala; Valbona Govori; Giuseppe Danilo Norata; Shaip Krasniqi
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

10.  Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02.

Authors:  Gwendolin S Simper; Gia-Gia T Hò; Alexander A Celik; Trevor Huyton; Joachim Kuhn; Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Döding
Journal:  J Immunol Res       Date:  2018-09-13       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.